In this review, we will shed light on the brief discussion of the targeting strategy of NK-based checkpoint receptors especially CD96 and NKG2A receptors with monoclonal antibodies to exploit the potential anti-tumor activity of NK cells as a helper of T cell-based checkpoint immunotherapy. This evidence concerns the gene CD96 and neoplasm.